FDA Approved: ADVAIR DISKUS — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for Advair Diskus (fluticasone propionate and salmeterol) from GlaxoSmithKline LLC under NDA 021077.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ADVAIR DISKUS (fluticasone propionate and salmeterol)

Snippet

SUPPL AP for ADVAIR DISKUS (FLUTICASONE PROPIONATE AND SALMETEROL)